Changes in the gut immune barrier in hepatic steatosis patients were observed in CII and AII tissue samples reported to controls (CD14+: CII: 44.37 ± 2.11; AII: 58.90 ± 4.52; vs. C: 41.64 ± 8.38, p > 0.05; IL-6+: CII: 48.73 ± 6.39; AII: 50.59 ± 3.06 vs. C: 30.83 ± 2.86; p > 0.05; p < 0.01; Figure 5A,B and Figure 6A,D,G,H,K,N). Here, IL6 is linked to fatty liver disease.